Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | CCR9 | P51686 | 9/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12242366 | 0.87 | LMNA (0.80) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL28006 | 0.85 | LMNA (0.86) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27979 | 0.84 | LMNA (0.83) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL13137558 | 0.82 | LMNA (0.80) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL28518 | 0.82 | LMNA (0.80) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL11182634 | 0.81 | LMNA (1.00) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL27758 | 0.81 | LMNA (0.78) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL2531519 | 0.81 | LMNA (0.82) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL28469 | 0.81 | CCR9 (0.79) | LMNAHTTCCR9TP53MAPT | |
| SCHEMBL12221183 | 0.81 | LMNA (0.73) | LMNAHTTCCR9TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | claimed |
| US-8642808-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-10-20 | — | — | US | disclosed |
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | disclosed |
| US-7335653-B2 | Chemokine receptor antagonists; CCR9-mediated disorders such as inflammatory and autoimmune diseases | CHEMOCENTRYX, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203131-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2005112916-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1567486-A2 | BIS-ARYL SULFONAMIDES | Chemocentryx (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
| US-20070203131-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885CCR9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.